TrialJournal of inherited metabolic disease2021

Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.

Eugen Mengel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.